Pacific Biosciences of California, Inc. (PACB) - Biznesning o‘zini qoplash muddati

PacBio Corp (PACB) korporativ emblemasi va logotipi

Pacific Biosciences Revio tizimlarini joriy etish orqali genom sekvensirlash bozorini qayta shakllantirishni va yordamchi reagentlar sotuvidan barqaror daromad oqimini ta'minlashni maqsad qilgan. -4.60 ko'rsatkichi bo'lgan aktivning narx trayektoriyasi kompaniyaning baholash dinamikasini aniq ifodalaydi. Murakkab patent himoyasi va ulkan R&D investitsiyalari bozorga kirishning yuqori to'sig'ini kafolatlaydi. Shu bilan birga, biznes energiya iste'molini optimallashtirish va plastik chiqindilarni kamaytirish orqali atrof-muhitga bo'lgan ta'sirini minimallashtiradi.

PACB (PacBio) P/E multiplikatori tarixi 04.07.2022dan 13.11.2026gacha

Pacific Biosciences of California (PACB) kompaniyasining tahliliy kesimlari

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari pacb.com|PACB - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor kapitallashuvi Pacific Biosciences of California, Inc.|PACB - Korxona qiymati
- balans kapitallashuvi bo'yicha ma'lumotlar:
Aksiyaning balans qiymati PacBio|PACB - Balans kapitallashuvi|Balans qiymatiga nisbatan bozor kapitallashuvi pacb.com|PACB - Kompaniyaning umumiy aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Pacific Biosciences|PACB - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati PacBio Corp|PACB - Kompaniyaning jamlangan qarzlari|Qarzning balans kapitallashuviga nisbati Pacific Biosciences of California, Inc.|PACB - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi PacBio|Shoshilinch likvidlik pacb.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
PACB - Kompaniyaning sof foydasi|Kompaniya foydasi prognozi Pacific Biosciences|PACB - P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Pacific Biosciences of California, Inc.|PACB - PEG multiplikatori|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Pacific Biosciences of California, Inc.|PACB - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda PacBio|PACB - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun foydaning yillik o'sishi pacb.com|PACB - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Pacific Biosciences
- kompaniyaning sotuvlari va tushumi statistikasi:
PACB - Daromad va sotish hajmi|Kompaniyaning kutilayotgan sotish hajmi pacb.com|PACB - Narxning daromadga nisbati|Kapitalizatsiyaning kutilayotgan sotuvga nisbati Pacific Biosciences of California, Inc.
Kompaniyaning jamlanma tahlili:pacb.com
PacBio Corp brend mahsuloti

Pacific Biosciences (PACB) o'sishi Revio tizimining kengayishi va yuqori marjali sarflanadigan materiallar savdosining ortishiga bog'liq. Ushbu jarayonlar natijasida yuzaga kelgan foyda dinamikasi kompaniyaning taxminiy P/E koeffitsiyentidagi maxrajni bevosita belgilaydi. Ushbu koeffitsiyent biznesning bozor qiymatini uning yillik sof foydasi bilan nisbatda aks ettirib, investitsiyalarning qoplanish muddatini o'lchaydi. Kompaniyaning taxminiy P/E koeffitsiyentiga asoslangan tahlil aktivlarning haddan tashqari qimmat baholanishi yoki yashirin past baholanish xatarlarini aniqlash imkonini beradi.

Muhim raqobatchilar

Narx-foyda koeffitsiyenti Tempus AI Inc (TEM)|P/E multiplikatori QGEN|Biznesning o‘zini qoplash muddati Ionis Pharmaceuticals, Inc.|P/E multiplikatori RGEN (Repligen Corp.)|RNA (Avidity Corp) - Kapitalizatsiyaning sof foydaga nisbati|CRISPR Therapeutics AG - P/E multiplikatori|Biznesning o‘zini qoplash muddati genedx.com WGS|RARE: P/E multiplikatori|Narx-foyda koeffitsiyenti Beam Therapeutics Inc|Narx-foyda koeffitsiyenti SRPT|TWST: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori TXG|Narxning foydaga nisbati NTLA (intelliatx.com)|P/E multiplikatori STOK (Stoke Therapeutics, Inc.)|Biznesning o‘zini qoplash muddati BioLife Solutions Inc (BLFS)|WVE - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Maze Therapeutics Corp|Sionna Therapeutics Inc (SION) - Narxning foydaga nisbati|PRME - Biznesning o‘zini qoplash muddati|TSHA (Taysha Gene Therapies, Inc.) - P/E multiplikatori|Narx-foyda koeffitsiyenti uniQure NV (QURE)|P/E multiplikatori MGTX|Biznesning o‘zini qoplash muddati REGENXBIO Corp|P/E multiplikatori SLDB (Solid Biosciences Inc.)|ocugen.com (OCGN) - Kapitalizatsiyaning foydaga nisbati|BNTC - Narxning foydaga nisbati|DSGN (Design Therapeutics Inc) - Narx-foyda multiplikatori|RCKT: P/E multiplikatori|Narx-foyda koeffitsiyenti 4D Molecular Corp|LXEO (Lexeo Therapeutics Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Korro Bio, Inc KRRO|Narxning foydaga nisbati Editas Medicine (EDIT)|Biznesning o‘zini qoplash muddati Silence Therapeutics PLC|Narxning foydaga nisbati ProQR Therapeutics PRQR|CDXS (Codexis Inc) - Kapitalizatsiyaning sof foydaga nisbati|Sangamo Therapeutics - P/E multiplikatori|NAUT - P/E multiplikatori|MGX: P/E multiplikatori|Narx-foyda koeffitsiyenti precisionbiosciences.com|GBIO (Generation Bio Co) - P/E multiplikatori|Narxning foydaga nisbati BOLD|P/E multiplikatori XCUR|imunon.com - Narx-foyda multiplikatori|Narxning foydaga nisbati Phio Pharmaceuticals Corp. PHIO|MBIO: Narx-foyda multiplikatori|TransCode - P/E multiplikatori|BNGO - P/E multiplikatori|Applied DNA Sciences (APDN) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati BLUE (bluebirdbio.com)|IPA (ImmunoPrecise Antibodies Ltd) - P/E multiplikatori|P/E multiplikatori Omega Therapeutics Inc|P/E multiplikatori OMIC|Narx-foyda koeffitsiyenti Regulus RGLS|P/E multiplikatori SYRS (Syros Pharmaceuticals)|Biznesning o‘zini qoplash muddati telesisbio.com (TBIO)|TRACON Pharmaceuticals, Inc. - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati UBX